This is a randomised, controlled, multi-centre clinical trial on AS patients. Experimental intervention: continuous (daily) treatment with diclofenac cholestyramine 150 mg (Voltaren Resinate), divided into 75mg Voltaren twice dailyControl intervention: treatment on-demand (as needed) with diclofenac-cholestyramine 75 to 150 mg (Voltaren Resinate). The treatment strategy of the control intervention (on-demand) reflects current clinical practice in AS. Duration of intervention per patient: 2 years Follow-up per patient: safety assessment 3 months after termination of the trial.
Ankylosing spondylitis (AS) is a common chronic inflammatory rheumatic disease with a prevalence of about 0.5%. First symptoms normally occur in young adulthood. Early in its course, AS is dominated by chronic pain, fatigue and morning stiffness, later on by ankylosis and loss of function. Nonsteroidal anti-inflammatory drugs (NSAID) and tumor necrosis factor (TNF) alpha blocking agents are the only drugs with proven efficacy for signs and symptoms. It is not clear, however, whether these drugs are also capable of retarding or stopping structural damage, i.e. prevention of bony ankylosis. Earlier investigations indicated that NSAIDs have, in addition to their anti-inflammatory, also an anti-osteoproliferative effect. In this study we will investigate whether treatment with 150 mg diclofenac, a non-selective NSAID, on a daily basis (continuous treatment) over 2 years is capable to slow down the development of bony ankylosis as compared to treatment with 75-150mg diclofenac as needed according to clinical symptoms (on-demand treatment). In this national multi-centre randomized trial patients with symptomatic AS and indication for NSAID therapy will be enrolled in about 40 centres. The primary outcome parameter is the proportion of patients with radiographic progression in the spine after 2 years in each treatment arm. If continuous NSAID treatment results in less radiographic progression as compared to on-demand treatment, a true disease modifying effect of NSAID has to be assumed which will most likely change the place of NSAID treatment in AS.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
180
continuous (daily) treatment of diclofenac cholestyramine 150 mg, divided into 75mg twice daily
treatment on-demand (as needed) with diclofenac-cholestyramine 75 to 150 mg daily
Medizinische Universitätsklinik Innere Medizin
Tübingen, Baden-Wurttemberg, Germany
Praxis Dr. Jacki
Tübingen, Baden-Wurttemberg, Germany
Praxis Dr. Manger
Bamberg, Bavaria, Germany
Praxis Dr. Ochs
Bayreuth, Bavaria, Germany
Praxis Dr. Kellner
München, Bavaria, Germany
Praxiszentrum St. Bonifazius
radiographic change (mean) of the spine after 2 years in the per-protocol population. Radiographs will be collected and centrally digitized. Scoring will be done by 2 readers who were blinded to treatment and sequence of the films
Time frame: 2 years
the proportions of patients with any progression (change in the mSASSS ≥ 1) and change in the mSASSS > smallest detectable change (SDC), i.e. change in mSASSS which is greater than the measurement error.
Time frame: 2 years
ITT analysis of radiographic change.
Time frame: 2 years
Change in VAS back pain, BASDAI, BASFI, BASMI, CRP.
Time frame: 2 years
event rates of serious and non-serious adverse events will be documented and compared between the two groups.
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
München, Bavaria, Germany
Gemeinschaftspraxis Dr. Göttl
Passau, Bavaria, Germany
Fachklinik Bad Bentheim
Bad Bentheim, Lower Saxony, Germany
Praxis Dr. Rockwitz
Goslar, Lower Saxony, Germany
Gemeinschaftspraxis Dr. von Hinüber
Hildesheim, Lower Saxony, Germany
...and 20 more locations